GlobeNewswire

XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis

Del

AUSTIN, Texas, Oct. 05, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD). XBiotech has now completed and exceeded enrollment in the final cohort of patients who are receiving 400mg weekly doses of bermekimab over an 8 week treatment period. Enrollment for the study is now closed.

XBiotech recently announced it completed the first cohort of patients in the study who received a low dose of bermekimab (200mg/weekly) over a 4 week treatment regimen. The Company reported that patients in the first cohort had significant improvement in multiple efficacy endpoints and that the treatment was well-tolerated.

XBiotech’s Medical Director, Mark Williams, M.D., M.B.A., commented, “I am extremely encouraged by an enrollment rate that has exceeded expectations. We look forward to completing the treatment protocol for our patients and evaluating the results.”

The phase 2, open label, dose escalation, multicenter study consists of two dose cohorts of bermekimab in patients with moderate to severe AD. Dose ranging in the study includes evaluation of the Company’s new highly-concentrated subcutaneous formulation. Nine patients in the first dosing cohort received a total of 4 weekly 200mg subcutaneous injections of bermekimab followed by safety assessments. Patients in the second cohort will receive 8 weekly 400mg subcutaneous injections of bermekimab for assessment of safety and preliminary efficacy.

Dr. Williams is as a medical director at XBiotech. He received his undergraduate degree in Human Biology at Stanford University and completed medical school at Yale. He also earned an MBA from the Stanford Graduate School of Business and has been awarded fellowships from the California Heart Association, the National Science Foundation and the Rand Corporation. Dr. Williams has conducted research in cardiology, biochemistry, analytic chemistry and health policy, and is published in a number of peer-reviewed journals.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com 
512-386-2930

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Elemica Wins Three Prestigious Supply Chain Awards This Month25.6.2019 17:03:00 CESTPressemelding

Elemica Awarded for Creating Supply Chain Excellence With Next-Gen Technologies ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces that the company has been honored with two top supply chain awards, and Gary Neights, Senior Director of Product Management at Elemica, was named a Top 50 Tech Visionary. “The industry is recognizing Elemica and its people for their innovative solutions and robust platform that produces exceptional business results for clients,” said David Cahn, Director of Global Marketing at Elemica. “Elemica has been instrumental this year in helping numerous global businesses move forward on their digital transformations, resulting in improved visibility, greater efficiencies, and better bottom line results.” Supply & Demand Chain Executive has selected Elemica as a recipient of the SDCE 100 Award for the 7th consecutive year. Food Logistics magazine has bestowed Elemica with a Top Green

cPacket Networks to Offer Cloud Visibility Service with Amazon Virtual Private Cloud Traffic Mirroring25.6.2019 17:00:00 CESTPressemelding

New cCloud Solution Provides Customers Access to Network-Level Packet Data for Performance and Security Monitoring SAN JOSE, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance/security monitoring and packet brokering solutions, has launched the cCloud cloud-based network visibility-as-a-service (VaaS) offering by working with Amazon Web Services (AWS) and leveraging the traffic mirroring feature offered by Amazon Virtual Private Cloud (Amazon VPC). “While many of our customers are migrating workloads to the cloud, until now it happened to be a black-box for them, from a performance and security perspective. The cPacket solution builds on Amazon Virtual Private Cloud (Amazon VPC) traffic mirroring to remove blind spots, provide complete visibility, and make the cloud transition smooth for our customers,” said Brendan O’Flaherty, CEO of cPacket Networks. Without the rich insights of packet data, full visibility is comprom

PowerPlan Expands Leadership Team To Support Continued Company Growth25.6.2019 16:42:00 CESTPressemelding

ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- PowerPlan, Inc., a leading provider of strategic corporate performance management for asset-intensive companies, announced today the appointment of Brett Bertz as its Chief Customer Officer and John Budala as its Chief Information Officer. These two positions, new to PowerPlan, will help the company sustain growth in the areas of customer success and technological infrastructure. Bertz and Budala report directly to the company’s CEO, Joe Gomes. “As PowerPlan continues to evolve to meet the needs of our customers, we are thrilled to have Brett and John join our leadership team,” said Gomes. “Brett and John have invaluable experience and have proven to lead through innovation.” Both Bertz and Budala join PowerPlan with extensive experience meeting and exceeding the needs of their customers, and building strong, progressive relationships with industry partners and their internal teams. Bertz has a history of building customer-centric cultures. He

NEP Group Acquires HDR, Expanding Its Broadcast and Media Solutions Capabilities in Europe and Worldwide25.6.2019 16:22:00 CESTPressemelding

PITTSBURGH, Pa. USA, June 25, 2019 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has signed a definitive agreement to purchase HDR Group, a full-service production partner headquartered in Stockholm, Sweden. The agreement became effective on June 17, 2019, and the deal is expected to close in early Q3 or Q4 of this year, conditional upon the approval of the Swedish Competition Authority. Prior to closing, NEP and HDR will continue to operate as separate and independent companies. HDR was founded in 2007 and today employs more than 100 employees who support clients in the live sports, entertainment and broadcast markets in Sweden, Norway, Denmark and Finland. The addition of HDR is consistent with NEP’s stated strategy to become the world leader in Broadcast Services and Media Solutions and increases NEP’s ability to serve its clients in the Nordic regi

Kim Crawford Wines Partners With US Open Tennis Championships25.6.2019 16:00:00 CESTPressemelding

No. 1-Selling Sauvignon Blanc in U.S. Becomes the Official Wine of the US Open Tennis Championships in New, Multi-Year Agreement WHITE PLAINS, N.Y. and MARLBOROUGH, New Zealand, June 25, 2019 (GLOBE NEWSWIRE) -- The United States Tennis Association (USTA) and Kim Crawford Wines today announced a new partnership that names Kim Crawford Wines as the official wine of the US Open Tennis Championships. The new, multi-year agreement commences with the 2019 Open. The No. 1-selling Sauvignon Blanci and leading New Zealand wine brandii in the U.S., Kim Crawford Wines will #ServeUpKim to US Open fans with a permanent brand presence on the grounds of the USTA Billie Jean King National Tennis Center. Kim Crawford will further support the partnership at retail locations across the country with impactful displays and an exciting sweepstakes, in which the winner will receive an all-expenses paid VIP experience at the 2020 US Open. The sweepstakes begins July 1 and ends August 31, during which consume

Appian Announces Winners of its Annual Hackathon at Appian World25.6.2019 15:00:00 CESTPressemelding

RESTON, Va., June 25, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) congratulates the winners of the Appian World 2019 Hackathon. Participants were tasked with leveraging the Appian platform to showcase the effectiveness and speed of low-code development. Hundreds of registrations were narrowed down to three winners by a seasoned panel of judges including Black Girls Code Founder and CEO, Kimberly Bryant and Neil Ward-Dutton, IDC’s VP of AI and DX European Research Practices and Appian executives. Finalists attended Appian World 2019 in San Diego, CA where they showcased their solutions to the all-star panel of judges. The judges based their decisions on the originality of the idea underlying the application, how well that idea was executed by the developer, and the beneficial impact of the solution. The submissions, covering a variety of industries and use cases, all exemplified the power and simplicity of building enterprise applications on the Appian platform. The 2019 winners are: